335 related articles for article (PubMed ID: 36834692)
21. Loss-of-function but not dominant-negative intragenic
Kobitzsch B; Gökbuget N; Schwartz S; Reinhardt R; Brüggemann M; Viardot A; Wäsch R; Starck M; Thiel E; Hoelzer D; Burmeister T
Haematologica; 2017 Oct; 102(10):1739-1747. PubMed ID: 28751559
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Wang H; Song C; Ding Y; Pan X; Ge Z; Tan BH; Gowda C; Sachdev M; Muthusami S; Ouyang H; Lai L; Francis OL; Morris CL; Abdel-Azim H; Dorsam G; Xiang M; Payne KJ; Dovat S
J Biol Chem; 2016 Feb; 291(8):4004-18. PubMed ID: 26655717
[TBL] [Abstract][Full Text] [Related]
23. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
24. [Ikaros Family Zinc Finger 1 Mutation Is an Adverse Prognostic Factor for Patients with Adult B-Cell Acute Lymphoblastic Leukemia].
Tang SH; Lu Y; Zhang PS; Liu XH; DU XH; Chen D; Pei RZ; Tang XW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):405-410. PubMed ID: 32319370
[TBL] [Abstract][Full Text] [Related]
25. Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.
de Rooij JD; Beuling E; van den Heuvel-Eibrink MM; Obulkasim A; Baruchel A; Trka J; Reinhardt D; Sonneveld E; Gibson BE; Pieters R; Zimmermann M; Zwaan CM; Fornerod M
Haematologica; 2015 Sep; 100(9):1151-9. PubMed ID: 26069293
[TBL] [Abstract][Full Text] [Related]
26. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Iacobucci I; Lonetti A; Messa F; Cilloni D; Arruga F; Ottaviani E; Paolini S; Papayannidis C; Piccaluga PP; Giannoulia P; Soverini S; Amabile M; Poerio A; Saglio G; Pane F; Berton G; Baruzzi A; Vitale A; Chiaretti S; Perini G; Foà R; Baccarani M; Martinelli G
Blood; 2008 Nov; 112(9):3847-55. PubMed ID: 18650450
[TBL] [Abstract][Full Text] [Related]
27. Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.
Rogers JH; Gupta R; Reyes JM; Gundry MC; Medrano G; Guzman A; Aguilar R; Conneely SE; Song T; Johnson C; Barnes S; Cristobal CDD; Kurtz K; Brunetti L; Goodell MA; Rau RE
Blood Adv; 2021 Oct; 5(19):3876-3890. PubMed ID: 34492683
[TBL] [Abstract][Full Text] [Related]
28. Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.
Churchman ML; Mullighan CG
Exp Hematol; 2017 Feb; 46():1-8. PubMed ID: 27865806
[TBL] [Abstract][Full Text] [Related]
29. Expression of aberrantly spliced oncogenic Ikaros isoforms coupled with clonal IKZF1 deletions and chimeric oncogenes in acute lymphoblastic leukemia.
Vshyukova V; Valochnik A; Meleshko A
Blood Cells Mol Dis; 2018 Jul; 71():29-38. PubMed ID: 29496375
[No Abstract] [Full Text] [Related]
30. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.
Iacobucci I; Lonetti A; Cilloni D; Messa F; Ferrari A; Zuntini R; Ferrari S; Ottaviani E; Arruga F; Paolini S; Papayannidis C; Piccaluga PP; Soverini S; Saglio G; Pane F; Baruzzi A; Vignetti M; Berton G; Vitale A; Chiaretti S; Müschen M; Foà R; Baccarani M; Martinelli G
Haematologica; 2008 Dec; 93(12):1814-21. PubMed ID: 18838475
[TBL] [Abstract][Full Text] [Related]
31.
Lopes BA; Barbosa TC; Souza BKS; Poubel CP; Pombo-de-Oliveira MS; Emerenciano M;
Cancer Prev Res (Phila); 2017 Dec; 10(12):738-744. PubMed ID: 28947432
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
33. The Genetic Variants of IKZF1 Gene Linked with the Growing Risk of Childhood Acute Lymphoblastic Leukaemia.
Tayel SI; El-Hefnway SM; Abo El-Fotoh WMM; El-Zayat RS
Curr Mol Med; 2019; 19(1):32-39. PubMed ID: 30806315
[TBL] [Abstract][Full Text] [Related]
34. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
[TBL] [Abstract][Full Text] [Related]
35. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia".
Palmi C; Lana T; Silvestri D; Savino A; Kronnie GT; Conter V; Basso G; Biondi A; Valsecchi MG; Cazzaniga G
Haematologica; 2013 Dec; 98(12):e164-5. PubMed ID: 24323991
[No Abstract] [Full Text] [Related]
36. [Ikaros family zinc finger 1 mutation is a poor prognostic factor for adult Philadelphia chromosome positive acute lymphoblastic leukemia].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Li SY; Cao JJ; Chen LG; Le J; Qian SY; Hong YW; Pei RZ
Zhonghua Nei Ke Za Zhi; 2019 Apr; 58(4):301-306. PubMed ID: 30917424
[No Abstract] [Full Text] [Related]
37. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.
Sun L; Goodman PA; Wood CM; Crotty ML; Sensel M; Sather H; Navara C; Nachman J; Steinherz PG; Gaynon PS; Seibel N; Vassilev A; Juran BD; Reaman GH; Uckun FM
J Clin Oncol; 1999 Dec; 17(12):3753-66. PubMed ID: 10577847
[TBL] [Abstract][Full Text] [Related]
38. Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.
Bond J; Domaschenz R; Roman-Trufero M; Sabbattini P; Ferreiros-Vidal I; Gerrard G; Asnafi V; Macintyre E; Merkenschlager M; Dillon N
Oncotarget; 2016 Oct; 7(40):65923-65936. PubMed ID: 27588474
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.
Churchman ML; Low J; Qu C; Paietta EM; Kasper LH; Chang Y; Payne-Turner D; Althoff MJ; Song G; Chen SC; Ma J; Rusch M; McGoldrick D; Edmonson M; Gupta P; Wang YD; Caufield W; Freeman B; Li L; Panetta JC; Baker S; Yang YL; Roberts KG; McCastlain K; Iacobucci I; Peters JL; Centonze VE; Notta F; Dobson SM; Zandi S; Dick JE; Janke L; Peng J; Kodali K; Pagala V; Min J; Mayasundari A; Williams RT; Willman CL; Rowe J; Luger S; Dickins RA; Guy RK; Chen T; Mullighan CG
Cancer Cell; 2015 Sep; 28(3):343-56. PubMed ID: 26321221
[TBL] [Abstract][Full Text] [Related]
40. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Dörge P; Meissner B; Zimmermann M; Möricke A; Schrauder A; Bouquin JP; Schewe D; Harbott J; Teigler-Schlegel A; Ratei R; Ludwig WD; Koehler R; Bartram CR; Schrappe M; Stanulla M; Cario G
Haematologica; 2013 Mar; 98(3):428-32. PubMed ID: 22875627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
